POLIVY delivers an anti-cancer drug to the B cell by attaching to a CD79b B cell surface marker.
After being taken into the B cell, POLIVY is broken down, releasing
the anti-cancer drug inside the B cell.
Once released, the anti-cancer drug in POLIVY causes the dividing B
cells to die, including the cancerous ones. It may also harm healthy
cells in the body.